ALFA Finder
The call ran from 11:01 AM to 11:47 AM IST (46 min).
Key takeaways
Suraksha delivered strong high double-digit growth in Q2 FY27, crossing the ₹100 crore revenue milestone. Expansion beyond West Bengal is progressing well, though seasonal festive dips are expected in Q3.
| Management target | Revenue 18.0% FY27 |
|---|
| Revenue growth | 26.4% YoY, driven by center maturation and network expansion. |
|---|---|
| Margins | EBITDA margin rose to 36.7%; targets 34-35% steady state next year. |
| Demand visibility | Strong visibility in genomics and specialized diagnostics; seasonal Q3 dip noted. |
| Management confidence | Confident and disciplined; focusing on cluster-building and operational leverage. |
Growth
Revenue grew 26.4% YoY; EBITDA margins expanded to 36.7% due to maturing centers.
Outlook
Management guides for 15-18% revenue growth for FY27 with steady 34-35% EBITDA margins.
Risks
Seasonal festive headwinds in Q3; execution risks in new geographies like Jharkhand and Tripura.
Last quarter's promises, checked
Delivered
- Guided EBITDA margin not below 34% for FY27 → delivered 36.7% (= BEAT)
- Guided ~20% quarterly revenue growth → delivered 26.4% YoY (= BEAT)
- Guided sub-2yr centre margin improvement from 6.5% → delivered 11.8% (= BEAT)
Partly delivered
- Guided Tripura hub 'will follow shortly' → now 'operations starting H2' (= PARTIAL)
Summary by ALFA Finder, written with AI assistance from our own recording of the call, published . Open it on ALFA Filings ›
The results behind this call
Suraksha Diagnostic Q2 FY27 Results: Net Profit ₹15 Cr, Up 70.5% YoY
Suraksha Diagnostic Ltd reported revenue from operations of ₹99.1 Cr (+25.9% YoY) and net profit of ₹15 Cr (+70.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹15 Cr · +70.5% YoY
What management said last time
Full summary →From the call summary published .
Outlook they gave
Management guides for 15% revenue growth for FY27 and plans to reach 100 centers by FY28.
Growth they described
Revenue grew 21% YoY; genomics vertical surged 136% YoY; EBITDA margins expanded to 36% from 34%.
Call details
| Company | Suraksha Diagnostic Ltd |
|---|---|
| NSE symbol | SURAKSHA |
| ISIN | INE877V01027 |
| Call | Q2 FY27 earnings call |
| Date | Friday, 13 November 2026 |
| Time | 11:00 AM IST |
| Length | 46 min |
| Audio | Our stream on YouTube ↗ |
Suraksha Diagnostic Ltd: key numbers
- Share price
- ₹347.70
- Market cap
- ₹1,811 Cr
- Revenue (annual)
- ₹310.4 Cr
- Net profit (annual)
- ₹32.19 Cr
- P/E (TTM)
- 43.3×Sector 54.7×
- Promoter holding
- 49.10%+0.00% QoQ
- FII holding
- 13.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Other calls on Fri, 13 Nov
Today's concalls →
